Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
New research explores how mitochondria-targeted peptide nanoparticles may protect the liver from ischemia-reperfusion injury. Learn what the science shows.
By Peptide Association Research Team
A 2026 ACS Nano study suggests mitochondria-targeted nanoparticles may reduce liver ischemia-reperfusion injury by limiting ROS and inflammation in mice.
By Peptide Association Research Team
New research explores how mitochondria-targeted polydopamine nanoparticles modified with SS-31 peptide may protect the liver from ischemia-reperfusion injury.
By Peptide Association Research Team